Greta Hultqvist

Uppsala university

Key Publications

Hultqvist, G., Syvänen, S., Fang, X. T., Lannfelt, L., & Sehlin, D. (2017).
Bivalent Brain Shuttle Increases Antibody Uptake by Monovalent Binding to the Transferrin Receptor.
Theranostics, 7(2), 308–318. https://doi.org/10.7150/thno.17155

Rofo, F., Ugur Yilmaz, C., Metzendorf, N., Gustavsson, T., Beretta, C., Erlandsson, A., Sehlin, D., Syvänen, S., Nilsson, P., & Hultqvist, G. (2021).
Enhanced neprilysin-mediated degradation of hippocampal Aβ42 with a somatostatin peptide that enters the brain.
Theranostics, 11(2), 789–804. https://doi.org/10.7150/thno.50263

Rofo, F., Metzendorf, N. G., Saubi, C., Suominen, L., Godec, A., Dag Sehlin, D., Syvänen, S., & Hultqvist, G. (2022).
Blood–brain barrier penetrating neprilysin degrades monomeric amyloid-beta in a mouse model of Alzheimer’s disease.
Alzheimer’s Research & Therapy, 14, 180. https://doi.org/10.1186/s13195-022-01132-2

Metzendorf, N. G., Godec, A., Petrovic, A., Chourlia, A., Napoleone, A., Syvänen, S., Rofo, F., & Hultqvist, G. (2025).
Somatostatin therapy, neprilysin activation, and amyloid beta reduction: A novel approach for Alzheimer’s treatment.
Biomedicine & Pharmacotherapy, 189, 118325. https://doi.org/10.1016/j.biopha.2025.118325

Morrison, J. I., Metzendorf, N. G., Rofo, F., Petrovic, A., & Hultqvist, G. (2023).
A single-chain fragment constant design enables easy production of a monovalent blood–brain barrier transporter and provides an improved brain uptake at elevated doses.
Journal of Neurochemistry, 165(3), 413–425. https://doi.org/10.1111/jnc.15768

Morrison, J. I., Petrovic, A., Metzendorf, N. G., Rofo, F., Yilmaz, C. U., Stenler, S., Laudon, H., & Hultqvist, G. (2023).
Standardized preclinical in vitro blood–brain barrier mouse assay validates endocytosis-dependent antibody transcytosis using transferrin-receptor–mediated pathways.
Molecular Pharmaceutics, 20(3), 1564–1576. https://doi.org/10.1021/acs.molpharmaceut.2c00768

We are developing protein- and AAV-based therapies for neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease. We handle the entire pipeline – from the design of the therapeutic construct to in vivo testing in murine disease models.

Therapeutic antibodies used today typically cannot cross cell membranes or the blood–brain barrier (BBB). The goal of our research is to open new possibilities: we design and evaluate multispecific antibodies where one part binds the pathogenic target (such as aggregated protein forms) and another part acts as a transporter to bring the therapeutic antibody to its target deep inside the brain. A major focus of our lab is to overcome the BBB, a notorious obstacle for large biologics such as antibodies, by exploiting receptor-mediated transport systems. We have, for example, engineered a “brain shuttle” by fusing single-chain variable fragments (scFv) targeting the transferrin receptor (TfR) to an antibody selective for amyloid-β (Aβ) protofibrils (Hultqvist et al. Theranostics 2017). This design allowed efficient receptor-mediated brain uptake: two hours after administration, concentrations of the modified antibody reached levels comparable to small molecule drugs in the brain, many times higher compared to unmodified antibodies. More recently, the group has developed an in vitro BBB model platform to evaluate and refine similar brain-delivery strategies, reducing reliance on animal experiments and accelerating preclinical screening for biologic therapies (Morrison JI et al. Mol Pharm 2023). 

Another focus of the research group is to identify and evaluate novel treatment strategies for neurodegenerative diseases, exemplified by studies where amyloid-beta degradation was induced in the hippocampus by upregulating the enzyme neprilysin via brain-targeting somatostatin (Hultqvist et al. Theranostics 2021, Rofo et al. ACS Chem Neurosci 2021, Metzendorf NG et al. Biomed Pharmacother 2025).

Group Members

Greta Hultqvist,
Doreen Dobritzsch,
Ana Godec,
Prune Leroy,
Jielu Liu,
Inga Petersen,
Bence Réthi,
Gustaf Hederoth,
Nicole Metzendorf

Last updated: 2025-12-05

Content Responsible: Hampus Pehrsson Ternström(hampus.persson@scilifelab.uu.se)